Yaniv Cohen was named Chief Effective Officer of IR-Med, Inc., effective September 14, 2026. As of November 6, 2026, IR-Med, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on September 15, 2026, naming 1 appointment (Form 8-K, September 15, 2026).
IR-Med, Inc. named a new Chief Effective Officer on Sep 15. 30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like IR-Med, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
IR-Med, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-09-15. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as IR-Med, Inc. files it.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-15 | In | Chief Effective Officer | 2026-09-14 | 8-K, 2026-09-15 |
Selling to them or working with them? See who runs IR-Med, Inc. now and the warning signs.
Free to see. No signup.
Watch IR-Med, Inc.
Get an email when IR-Med, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on IR-Med, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on IR-Med, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on IR-Med, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Who leads IR-Med, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Effective Officer: Yaniv Cohen, appointed, effective 2026-09-14 (filed 2026-09-15).
New leaders reset buying decisions — get the Full Report on IR-Med, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Effective Officer at IR-Med, Inc., with the record behind each one.
Find candidates like Chief Effective Officer at IR-Med, Inc.Every change, in the filing's words
Appointed: Yaniv Cohen, Chief Effective Officer, effective 2026-09-14
On September 14, 2026, the Board of Directors (the "Board") of IR-Med, Inc. (the "Company") appointed Yaniv Cohen, as interim Chief Effective Officer of the Company, effective as of September 14, 2026.
- Med Ltd. in September 2013 and has served as the R&D manager.
- Following the completion of the acquisition of IR.
- Med Ltd he serves as the CSO. and was appointed to the Board.
- Mr. Cohen is an experienced electrical engineer with expertise in the fields of wave propagation and IR Spectroscopy for medical applications.
- Additionally, Mr. Cohen holds four patents in medical devices, has co-authored eight articles in scientific journals, and has spoken in conferences around the globe.
- From 2010 to 2013, Mr. Cohen served as R&D manager for PIMS, an Israeli medical device company, focusing on IR imaging and spectral analysis for non-invasive cancer assessment and identification.
- From 2008 to 2009, Mr. Cohen worked for Cisco as a system engineer.
- From 2006 to 2008, he worked as a service engineer for Intel Israel.
- Since 2022, Mr. Cohen holds a Ph.D of Sciences in the doctoral program, Informatics and Computer Engineering in the National Research University Higher School of Economics, School of Electronic Engineering Institute of Electronics and Mathematics (MIEM HSE) in Moscow, Russia.
- Mr. Cohen holds a M.Sc. in Electrical Engineering from Holon Institute of Technology (2007).
- From 2009 to 2010, he attended the Ben-Gurion University of the Negev, Beer Sheva, Israel where he wrote a thesis in wave prorogation.
Tools for this story
Each opens in a new tab, filled in for IR-Med, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.